RxDoctor Payments Data

Randy Kaplan

Podiatrist · West Bloomfield, MINPI 1649256991

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $6,290 of the $8,414 with a category attached, or 74.8%. 38 manufacturers reported payments, led by ETS Wound Care LLC at 28.1% of the total. 2025 is the largest year on record at $3,193, 5.1 times the $629 reported in 2019. Among podiatrist clinicians in MI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$8,414in general payments, 2019–2025

Across 163 payments — averaging $51.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ETS Wound Care LLC$2K
  • Aroa Biosurgery Incorporated$713
  • Organogenesis Inc.$626
  • Nevro Corp.$446
  • Smith+Nephew$446
  • Johnson & Johnson$358
  • plus $3K from 32 others

What the payments were for

  • Speaking & faculty fees$791%
  • Travel & lodging$1,36616%
  • Food & beverage$6,29075%
  • Education$6788%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,414 in reported general payments places this provider in the 90th percentile of 302 podiatrist providers in Michigan.

See all podiatrist providers in Michigan

Medicare billing

Part B allowed, 2024
$123,579
Medicare patients
336
Services billed
1,832

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SantylCollagenase Clostridium Hist.21$21,636

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Smith+NephewSantyl$446$21,63621 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 302 podiatrist providers in Michigan.

Other podiatrist in West Bloomfield

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →